These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2817803)

  • 1. Erythrocyte membrane-bound daunorubicin as a delivery system in anticancer treatment.
    Gaudreault RC; Bellemare B; Lacroix J
    Anticancer Res; 1989; 9(4):1201-5. PubMed ID: 2817803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoerythrosome, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin.
    Lejeune A; Moorjani M; Gicquaud C; Lacroix J; Poyet P; Gaudreault R
    Anticancer Res; 1994; 14(3A):915-9. PubMed ID: 8074493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoerythrosomes, a new derivative of erythrocyte ghost II: identification of the mechanism of action.
    Moorjani M; Lejeune A; Gicquaud C; Lacroix J; Poyet P; Gaudreault RC
    Anticancer Res; 1996; 16(5A):2831-6. PubMed ID: 8917393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoerythrosomes, a new derivative of erythrocyte ghost: III. Is phagocytosis involved in the mechanism of action?
    Lejeune A; Poyet P; Gaudreault RC; Gicquaud C
    Anticancer Res; 1997; 17(5A):3599-603. PubMed ID: 9413209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms.
    Marchini S; Damia G; Broggini M; Pennella G; Ripamonti M; Marsiglio A; Geroni C
    Cancer Res; 2001 Mar; 61(5):1991-5. PubMed ID: 11280757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythrocyte entrapment of daunomycin by amphotericin B without hemolysis.
    Kitao T; Hattori K
    Cancer Res; 1980 Apr; 40(4):1351-3. PubMed ID: 7357561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daunorubicin coupled to monoclonal antibodies via a cis-aconitic anhydride linker: biochemical and cytotoxic properties revisited.
    Ahmad A; Law KL; Young B; Telander MW; Ogden JR; Leung K
    Anticancer Res; 1990; 10(3):837-43. PubMed ID: 2369097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer.
    Yokoyama M; Miyauchi M; Yamada N; Okano T; Sakurai Y; Kataoka K; Inoue S
    Cancer Res; 1990 Mar; 50(6):1693-700. PubMed ID: 2306723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo cytotoxicity and antineoplastic activity of a transferrin-daunorubicin conjugate.
    Lemieux P; Pagé M; Noël C
    In Vivo; 1992; 6(6):621-7. PubMed ID: 1296812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor reactive cis-aconitylated monoclonal antibodies coupled to daunorubicin through a peptide spacer are unable to kill tumor cells.
    Law KL; Studtmann KE; Carlson RE; Swanson TA; Buirge AW; Ahmad A
    Anticancer Res; 1990; 10(3):845-52. PubMed ID: 2369098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the toxicity and therapeutic efficacy of daunorubicin linked with a biodegradable carrier.
    Hrdina R; Bogusová TA; Kunová A; Kvĕtina J
    Neoplasma; 1991; 38(3):265-73. PubMed ID: 1857447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and cytotoxic activity of 1-(3-oxoprop-1-enyl)-2-pyridones.
    Ho LK; Knaus EE; Allen TM; Fathi-Afshar R
    Drug Des Deliv; 1988 Feb; 2(3):227-37. PubMed ID: 3255317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of selected daunorubicin derivatives in mice with P 388 leukemia.
    Kuśnierczyk H; Rak J; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1986; 34(3):259-62. PubMed ID: 3592929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction of DNR and glutaraldehyde with cell membrane proteins leads to morphological changes in erythrocytes.
    Marczak A; Jóźwiak Z
    Cancer Lett; 2008 Feb; 260(1-2):118-26. PubMed ID: 18060688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of daunorubicin linked to poly-L-aspartic acid.
    Zunino F; Giuliani F; Savi G; Dasdia T; Gambetta R
    Int J Cancer; 1982 Oct; 30(4):465-70. PubMed ID: 7141741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug.
    Szabó I; Manea M; Orbán E; Csámpai A; Bosze S; Szabó R; Tejeda M; Gaál D; Kapuvári B; Przybylski M; Hudecz F; Mezo G
    Bioconjug Chem; 2009 Apr; 20(4):656-65. PubMed ID: 19296605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased therapeutic efficacy and reduced toxicity of doxorubicin linked to pyran copolymer via the side chain of the drug.
    Zunino F; Pratesi G; Pezzoni G
    Cancer Treat Rep; 1987 Apr; 71(4):367-73. PubMed ID: 3829013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug.
    Dillman RO; Johnson DE; Shawler DL; Koziol JA
    Cancer Res; 1988 Nov; 48(21):6097-102. PubMed ID: 3262420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.
    Forssen EA; Malé-Brune R; Adler-Moore JP; Lee MJ; Schmidt PG; Krasieva TB; Shimizu S; Tromberg BJ
    Cancer Res; 1996 May; 56(9):2066-75. PubMed ID: 8616852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.